Thermo Fisher Scientific has entered into a significant agreement with Chinese cell therapy leader JW Therapeutics, granting non-exclusive commercial access to its Gibco CTS Dynabeads CD3/CD28 technology. This collaboration is set to accelerate the clinical development and commercial manufacturing of CAR-T therapies in China, focusing on JW Therapeutics’ pioneering product, relmacabtagene autoleucel (relma-cel). Enhancing CAR-T […]
Thermo Fisher Scientific has agreed to acquire California-based point-of-care molecular diagnostic company Mesa Biotech in a deal worth up to $500 million. The consideration includes nearly $450 million in cash and an additional amount of up to $100 million, which will be subject to Mesa Biotech achieving certain milestones post-acquisition. The molecular diagnostic company has […]
Thermo Fisher Scientific has completed the acquisition of Groupe Novasep’s acquisition of viral vector manufacturing business in Belgium – Henogen for nearly €725 million in cash. The divested viral vector manufacturing business of Novasep offers contract manufacturing services for vaccines and therapies to biotech firms and large biopharma customers. Through its two locations in Seneffe […]
Thermo Fisher Scientific has officially inaugurated a new $40 million facility for manufacturing COVID-19 sample collection products in Lenexa, Kansas, which will exclusively produce viral transport media (VTM). The life sciences company said that the Lenexa site will continue to be expanded to cope up with the expected continued demand for COVID-19 testing. The facility, […]
Thermo Fisher Scientific has scrapped its previously planned $11.5 billion acquisition of Qiagen after its offer to buy all of the ordinary shares of the latter lapsed. The US life sciences company announced the acquisition of the Netherlands-based provider of molecular diagnostics and sample preparation technologies in March 2020 in a move to expand specialty […]
US life sciences company Thermo Fisher Scientific said that it will collaborate with China-based WuXi Diagnostics and Mayo Clinic to develop a total antibodies Covid-19 test called the Thermo Scientific OmniPath COVID-19 Total Antibody ELISA test. The new antibody test development is said to emerge from an ongoing partnership between the three organizations, which includes […]
Thermo Fisher acquisition of Qiagen : US life sciences company Thermo Fisher Scientific has agreed to acquire Qiagen, a Netherlands-based provider of molecular diagnostics and sample preparation technologies in an all-cash deal worth around $11.5 billion. The deal includes the assumption of nearly Qiagen’s $1.4 billion of net debt by the US firm. Thermo Fisher […]
Thermo Fisher Scientific has been granted an emergency use authorization (EUA) for its coronavirus diagnostic test from the US Food and Drug Administration (FDA). The FDA authorization allows Thermo Fisher Scientific’s COVID-19 diagnostic test that can be immediately used by CLIA high-complexity laboratories in the US for the detection of nucleic acid from SARS-CoV-2, the […]
Global life sciences company Thermo Fisher Scientific has agreed to acquire Massachusetts-based Brammer Bio from Ampersand Capital Partners for about $1.7 billion in cash. Brammer Bio is a viral vector contract development and manufacturing organization (CDMO) serving bipharma companies seeking to develop and commercialize gene therapies. The CDMO was formed in 2016 through the merger […]
Thermo Fisher Scientific, a Massachusetts-based biotech product development company has acquired California-based IntegenX, which offers a rapid DNA technology for human identification for forensic and law enforcement agencies. Financial terms of Thermo Fisher acquisition of IntegenX have not been disclosed by the parties. According to Thermo Fisher, IntegenX products will boost its existing HID portfolio to […]